Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sun Yat-sen University
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1.18 years or older 2. Eastern Cooperative Oncology Group performance status: 0 or 1 3. Clinical stage IB to IIIB (T3-4N2) Resectable NSCLC 4. Adequate cardiopulmonary and haematological function.
You may not be if
1. Known EGFR-sensitising mutations and EML4-ALK fusions
2. Concomitant malignancy, history of another cancer within the past 3 years.
3. Current or previous use of immunosuppressive medication,active autoimmune disease, and interstitial lung disease or idiopathic pulmonary fibrosis on a screening radiographic scan
Clareo Health | Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC
